HCPCS Level II
J9260
Injection, methotrexate sodium, 50 mg
Codes near J9260
These sit next to J9260 in the CMS Level II file. All J codes
- J9250Methotrexate sodium, 5 mg
- J9255Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg
- J9256Injection, nipocalimab-aahu, 3 mg
- J9258Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
- J9259Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
- J9261Injection, nelarabine, 50 mg
- J9262Injection, omacetaxine mepesuccinate, 0.01 mg
- J9263Injection, oxaliplatin, 0.5 mg
- J9264Injection, paclitaxel protein-bound particles, 1 mg
- J9265Injection, paclitaxel, 30 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00143-9367-01 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 20 |
| 00143-9519-10 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 10 |
| 00143-9830-01 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 20 |
| 00703-3671-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 1 |
| 00703-3675-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 5 |
| 00703-3678-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 20 |
| 00703-3678-81 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 20 |
| 16729-0277-03 | Methotrexate Sodium | ACCORD HEALTHCARE INC | 5 |
| 16729-0277-30 | Methotrexate Sodium | Accord Healthcare Inc | 1 |
| 16729-0277-35 | Methotrexate Sodium | Accord Healthcare Inc | 20 |
| 61703-0124-40 | Methotrexate Sodium | Pfizer Inc | 20 |
| 61703-0161-05 | Methotrexate Sodium | Pfizer Inc | 5 |
| 61703-0350-10 | Methotrexate Sodium | Pfizer Inc | 5 |
| 61703-0350-38 | Methotrexate Sodium | Pfizer Inc | 5 |
| 61703-0408-25 | Methotrexate Sodium | Pfizer Inc | 20 |
| 61703-0408-41 | Methotrexate Sodium | Pfizer Inc | 20 |
| 63323-0122-50 | Methotrexate Sodium | FreseniUS Kabi USA, LLC | 20 |
| 63323-0123-10 | Methotrexate Sodium | FreseniUS Kabi USA, LLC | 5 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.